Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharmace (MEDXF) is a North American specialty pharmaceutical leader focused on innovative therapies for complex conditions in oncology, hematology, and rheumatology. This page provides investors and healthcare professionals with essential updates on the company's latest developments.
Access timely press releases covering regulatory milestones, product launches, financial results, and strategic partnerships. Our curated news collection helps stakeholders track MEDXF's progress in commercializing treatments for rare diseases and autoimmune disorders.
Key updates include FDA/Health Canada submissions, licensing agreements, clinical trial developments, and market expansion initiatives. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for direct access to MEDXF's official announcements and analysis of its growing role in specialty pharmaceuticals. Check regularly for updates demonstrating the company's commitment to addressing unmet medical needs through targeted therapeutic solutions.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) reported fiscal Q1 2025 results with revenue of $27.3 million, a 13.6% decrease from Q1 2024. The company achieved net income of $2.0 million, up from $0.7 million in Q1 2024, and Adjusted EBITDA of $6.1 million. Key highlights include:
- Strong performance of Rupall during allergy season
- FDA acceptance of treosulfan NDA resubmission, with decision expected by October 30, 2024
- Positive cash flow and record quarterly operating cash flow of $8.2 million
- Implementation of cost reduction initiatives
- Ongoing negotiations with medac regarding treosulfan agreement
The company faces challenges with IXINITY and Rasuvo sales but remains optimistic about treosulfan's potential in the US market, targeting a commercial launch in the first half of 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has announced a conference call scheduled for August 8, 2024, at 8:00 am Eastern Time to discuss the company's financial results for the first fiscal quarter ended June 30, 2024. The company plans to file its financial statements and MD&A after market close on August 7, 2024.
Investors can participate in the call using the provided toll-free numbers for Canadian and U.S. callers, or the international number. A live webcast will be available on Medexus's corporate website. A replay of the call will be accessible until August 15, 2024, and a webcast replay will be available until August 8, 2025.
Medexus Pharmaceuticals reported record revenue of $113.1 million for fiscal year 2024, a 4.6% increase from $108.1 million in 2023. This growth was driven by full recognition of Gleolan sales and strong demand for Rupall, offset by declines in IXINITY and Rasuvo sales.
Revenue for Q4 2024 was $26.0 million, down 9.1% from $28.6 million in Q4 2023. Adjusted EBITDA hit a record $19.5 million for the year, a 20.9% increase. However, Q4 2024 Adjusted EBITDA decreased to $4.4 million from $4.8 million in Q4 2023.
Operating income for the year was $10.8 million, but Q4 saw a decrease to $0.8 million. The company reported a net loss of $0.2 million for fiscal year 2024 and net income of $0.8 million for Q4 2024. Cash and cash equivalents were $5.3 million as of March 31, 2024, down from $13.1 million the previous year.
The FDA has accepted Medexus's partner medac's resubmission for treosulfan's NDA, with a decision expected by October 30, 2024.
Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) has announced it will host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024, to discuss its fourth fiscal quarter and fiscal year results ending March 31, 2024. The financial statements and MD&A will be filed after markets close on June 25, 2024. Interested parties can join the call via toll-free numbers for Canadian and U.S. callers or through an international number with the access code 160589. A live webcast will be available on Medexus's investor section of their website. A replay will be accessible approximately one hour post-call and until July 3, 2024, through specified phone numbers and on the website until June 26, 2025.
On June 6, 2024, Medexus Pharmaceuticals announced that the US FDA has accepted for review the resubmission of the New Drug Application (NDA) for treosulfan, a drug used in combination with fludarabine for stem cell transplantation in both adult and pediatric patients. The review is expected to be completed by October 30, 2024. This resubmission includes additional data from a pivotal Phase 3 clinical trial. CEO Ken d'Entremont expressed optimism about the drug's approval and its potential to significantly impact Medexus's revenue if approved in the US. Treosulfan has already been successfully commercialized in Canada under the brand name Trecondyv® since September 2021.
Medexus Pharmaceuticals and medac have concluded the litigation regarding the Canadian patent for Metoject® after a trial in January 2023. The Federal Court of Canada declined to uphold the patent, leading to no meaningful changes for Medexus's business. The company remains optimistic about the impact of this outcome on their product and operations.
FAQ
What is the current stock price of Medexus Pharmace (MEDXF)?
What is the market cap of Medexus Pharmace (MEDXF)?
